Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma.
Philippe Fonteyne(University Medical Center Groningen), Christophe Van de Wiele(Ghent University), Marc Peeters(University of Antwerp), Patrick Pauwels(University of Antwerp), Veerle Casneuf(Ghent University Hospital), Nancy Van Damme, Rudi Dierckx(University Medical Center Groningen)
Cited by 20
Related Papers
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
|Molecular Neurobiology|2018|750
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
|Journal of Nuclear Medicine|2009|562
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
|Annals of Oncology|2009|534
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
|The Lancet Oncology|2017|510